Last reviewed · How we verify

NCT04544696

Pharmacist for Detecting Opioid Misuse

Completed Last updated 14 September 2020
What this trial tests

trial in Chronic Non Cancer Pain in 414 participants. Completed in 1 June 2019.

Timeline
17 April 2019
Primary endpoint
1 June 2019
1 June 2019

Quick facts

Lead sponsorUniversity Hospital, Montpellier
StatusCompleted
Study typeOBSERVATIONAL
Enrollment414
Start date17 April 2019
Primary completion1 June 2019
Estimated completion1 June 2019
Sites1 location across France

Conditions studied

Sponsor

University Hospital, Montpellier

Who can join

18 and older, any sex, with Chronic Non Cancer Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Opioid use is increasing in Western countries and is associated with harms as hospitalization, addiction and deaths(1). Community pharmacists interact frequently with patients, giving them the opportunity to identify and prevent the risk of prescribed opioid misuse. The purpose of this study was therefore to assess the risk of prescribed opioids misuse in ambulatory patients with chronic non-cancer pain (CNCP) seen in community pharmacies. Method: A questionnaire (including the Prescription Opioid Misuse POMI(2)) have been proposed to patients with opioid prescription by pharmacy students, in 86 pharmacies of Occitanie-Est, in April 2019. Eligible patients were adults with CNCP that consented to participate. A total of 414 patients (62.4% women, mean age 58 ± 16.00) have been included. The main pains were spinal (37.3%) and osteoarticular (33.1%). The median visual analog scale (VAS) was 7 \[IQR25-75: 5-8\]. The prescribed opioids are mainly weak opioids (73.2%): paracetamol/tramadol (35%), paracetamol/codeine (17.4%), paracetamol/opium (16.8%). Strong opioids (32.6%) were oxycodone (11.95%), fentanyl (9%), and morphine (9%). The median morphine milligram equivalent (MME) was 40 mg/day \[IQR25-75: 20-80\]. POMI score was superior to 2/6 in 45.4% and superior to 4 in 16%. The main positive question were feel high (40.3%), take the opioid more often (39.3%), take more medication (36.6), and need to early renew opioid medication earlier (30.8%). Patients with POMI score \> 4 were younger (49 years versus 55.9; p\<0.01), more urban (78.1% versus 69.2%; p=0.03), had higher VAS (7.3 versus 6.2; p\<0.01), received higher median MME (112 mg versus 64.9 mg; p\<0.01), and consumed more strong opioid (45.3% versus 27.3%; p=0.04).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University Hospital, Montpellier trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04544696.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing